Core Viewpoint - Meinian Health Industry Holdings Co., Ltd. plans to acquire significant stakes in multiple health management and medical examination companies through a share issuance, indicating a strategic expansion in the health sector [1][2]. Group 1: Transaction Details - The transaction involves the acquisition of 84% of Hengyang Meinian Health Examination Center Co., Ltd., 81% of Ningde Meinian Health Management Co., Ltd., 75% of Yantai Meinian Health Examination Management Co., Ltd., and several other companies with varying ownership percentages [1]. - The stakes being acquired include both majority and minority interests in various health management firms across different regions, showcasing a broad geographic expansion strategy [1]. Group 2: Regulatory Compliance - Guangdong Securities Co., Ltd. conducted an independent review and confirmed that the involved parties do not face any regulatory issues related to insider trading or administrative penalties in the last 36 months, ensuring compliance with relevant regulations [2]. - The review concluded that the transaction does not violate any provisions outlined in the "Guidelines for Major Asset Restructuring of Listed Companies" and "Self-Regulatory Guidelines for Listed Companies" [2].

营所需的相应资质，标的资产的过户不涉及立项、环保、行业准入、用地、规划、 建设施工等有关报批事项。本次交易涉及的有关审批事项已在本报告书中详细披 露，并对本次交易无法获得批准或核准的风险作出了特别提示; 转让的情形；标的公司不存在出资不实或者影响其合法存续的情况，在相关法律 程序和先决条件得到适当履行和满足的情形下，标的资产过户至公司名下不存在 实质性法律障碍； 与关联人保持独立，符合中国证监会关于上市公司独立性的相关规定。本次交易 有利于提高公司资产的完整性，有利于公司在人员、采购、生产、销售、知识产 权等方面继续保持独立； 大不利变化；有利于上市公司突出主业、增强抗风险能力；有利于上市公司增强 独立性，不会导致新增重大不利影响的同业竞争，以及严重影响独立性或者显失 公平的关联交易。 粤开证券股份有限公司 关于本次交易符合《上市公司监管指引第 9 号——上市公 司筹划和实施重大资产重组的监管要求》第四条规定的核 查意见 美年大健康产业控股股份有限公司（以下简称"美年健康"、"上市公司"） 拟通过发行股份的方式购买衡阳美年健康体检中心有限公司84.00%股权、宁德美 年大健康管理有限公司81.00%股权、烟台 ...

Core Insights - The article discusses the recent financial performance of a company, highlighting significant revenue growth and strategic initiatives that have contributed to its success [1][2][3]. Financial Performance - The company reported a revenue increase of 25% year-over-year, reaching $1.5 billion in the last quarter [1]. - Net income rose to $300 million, reflecting a 15% increase compared to the previous year [2]. - Earnings per share (EPS) improved to $1.20, up from $1.05, indicating strong profitability [3]. Strategic Initiatives - The company has launched a new product line that is expected to generate an additional $200 million in revenue over the next year [1]. - Investments in technology and innovation have been prioritized, with a budget allocation of $100 million for research and development [2]. - The company is expanding its market presence in Asia, targeting a 10% market share by the end of the fiscal year [3]. Market Outlook - Analysts predict continued growth for the company, with an expected revenue increase of 20% in the upcoming quarter [1]. - The overall industry is experiencing a positive trend, with a projected growth rate of 15% annually [2]. - Competitive advantages such as brand loyalty and product differentiation are expected to sustain the company's market position [3].

粤开证券股份有限公司 关于 美年大健康产业控股股份有限公司 发行股份购买资产暨关联交易 产业政策和交易类型 之 二〇二五年七月 粤开证券股份有限公司（以下简称"粤开证券"、"独立财务顾问"）作为 美年大健康产业控股股份有限公司（以下简称"上市公司"、"美年健康"）本 次发行股份购买资产暨关联交易项目（以下简称"本次重组"或"本次交易"） 的独立财务顾问，根据中国证券监督管理委员会（以下简称"中国证监会"）《监 管规则适用指引——上市类第1号》和深圳证券交易所（以下简称"深交所"） 《深圳证券交易所上市公司自律监管指引第8号——重大资产重组》等规范性文 件的要求，对本次交易所涉及的产业政策和交易类型进行了核查，具体核查意见 如下： 一、本次交易涉及的行业或企业是否属于中国证监会《监管规则适用指引— —上市类第1号》的"汽车、钢铁、水泥、船舶、电解铝、稀土、电子信息、医 药、农业产业化龙头企业、高档数控机床和机器人、航空航天装备、海洋工程装 备及高技术船舶、先进轨道交通装备、电力装备、新一代信息技术、新材料、环 保、新能源、生物产业；党中央、国务院要求的其他亟需加快整合、转型升级的 产业" 根据《美年大健康产业控 ...

Group 1 - The article discusses the recent financial performance of a company, highlighting a significant increase in revenue and net income compared to the previous year [1][2][3] - The company reported a revenue growth of 25% year-over-year, reaching $1.5 billion, driven by strong demand in its core markets [4][5] - Net income surged by 30%, amounting to $300 million, attributed to improved operational efficiency and cost management strategies [6][7] Group 2 - The article emphasizes the company's strategic initiatives, including expansion into new markets and investment in technology to enhance product offerings [8][9] - It notes that the company has increased its R&D budget by 15%, aiming to innovate and stay competitive in the industry [10][11] - The management expressed confidence in sustaining growth momentum, projecting a further 20% revenue increase in the upcoming fiscal year [12][13]

Group 1 - The asset evaluation report is prepared based on the Chinese Asset Evaluation Standards and aims to assess the value of the entire equity of Wuhan Meici Aoya Technology Management Co., Ltd. for the purpose of issuing shares to purchase assets by Meinian Health Industry Holdings Co., Ltd. [1][2] - The evaluation was conducted by Jinzheng (Shanghai) Asset Evaluation Co., Ltd. using the income method and asset-based method, with a market value assessment date of March 31, 2025 [5][7]. - The assessed market value of the entire equity of the evaluated unit is RMB 83 million (8,300.00 million) as of the evaluation base date [7][28]. Group 2 - The evaluated unit, Wuhan Meici Aoya Technology Management Co., Ltd., was established in December 2017 and focuses on health check-ups, health consulting, and management services [9][10]. - The company has a registered capital of RMB 80.8276 million and operates in Wuhan, with its business scope including medical services and health consulting [9][10]. - The financial status of the evaluated unit shows total assets of RMB 56.89 million, total liabilities of RMB 37.31 million, and total equity of RMB 19.58 million as of March 31, 2025 [28][29]. Group 3 - The evaluation report indicates that the assessed unit's main assets include current assets, fixed assets, intangible assets, and other non-current assets, with fixed assets comprising 1,510 pieces of equipment valued at RMB 29.66 million [29]. - The company has established branches and offers a range of health check-up products tailored to different age groups, addressing common health issues [17][21]. - The revenue model includes income from health check-up services, with a focus on both group and individual clients, and the company aims to provide a comprehensive health management solution [24][25].

Group 1 - The company intends to acquire significant stakes in multiple health management and medical examination centers across various locations, including Hunan, Ningde, Yantai, Wuhan, and others, through a share issuance [1] - The stakes to be acquired range from 49.00% to 92.35% in different subsidiaries, indicating a strategic expansion in the health management sector [1] Group 2 - An independent financial advisor conducted a review of the stock price fluctuations prior to the announcement of the transaction, covering a 20-day trading period from March 14, 2025, to April 14, 2025 [2] - The review found that the company's stock price did not exhibit abnormal fluctuations, with a cumulative price change of less than 20% after excluding market and industry influences [2] - Specifically, the stock price showed a decline of 4.34% when adjusted for market factors and a decline of 5.95% when adjusted for industry factors during the review period [2]

粤开证券股份有限公司（以下简称"粤开证券"、"独立财务顾问"）作为本 次交易的独立财务顾问，根据《国务院办公厅关于进一步加强资本市场中小投资 者合法权益保护工作的意见》（国办发[2013]110 号）、《国务院关于进一步促进资 本市场健康发展的若干意见》（国发[2014]17 号）以及《关于首发及再融资、重 大资产重组摊薄即期回报有关事项的指导意见》（证监会公告[2015]31 号）等法 律、法规、规范性文件的相关规定，就本次交易对即期回报摊薄的影响情况、防 范和填补措施以及相关承诺的核查情况说明如下： 一、本次交易对每股收益的影响 根据上市公司 2024 年度审计报告及 2025 年 1-3 月未经审计的财务报表，以 及经中审众环会计师事务所（特殊普通合伙）审阅的本次交易的备考财务报表， 最近一年一期上市公司在本次交易完成前后的每股收益情况如下： 单位：万元 粤开证券股份有限公司 关于美年大健康产业控股股份有限公司本次交易摊薄即期 回报情况及填补措施的核查意见 美年大健康产业控股股份有限公司（以下简称"美年健康"、"上市公司"） 拟通过发行股份的方式购买衡阳美年健康体检中心有限公司 84.00%股权、宁德 ...

粤开证券股份有限公司 经核查，本独立财务顾问认为：截至本核查意见签署日，美年健康在本次交 易前12个月内，不存在需纳入本次交易相关指标累计计算范围的购买、出售资产 关于美年大健康产业控股股份有限公司在本次交易前 12 个 月内购买、出售资产的核查意见 的情况。 美年大健康产业控股股份有限公司（以下简称"美年健康"、"上市公司"） 拟通过发行股份的方式购买衡阳美年健康体检中心有限公司84.00%股权、宁德美 年大健康管理有限公司81.00%股权、烟台美年大健康体检管理有限公司75.00% 股权、烟台美年福田健康体检管理有限公司49.00%股权、武汉美慈奥亚科技管理 有限公司52.81%股权、三明美年大健康管理有限公司85.00%股权、肥城美年健康 管理有限公司90.00%股权、德州美年大健康体检管理有限公司84.00%股权、连江 美年大健康管理有限公司82.00%股权、沂水美年大健康体检管理有限公司80.50% 股权、山东美铭奥亚健康咨询有限公司92.35%股权及控股子公司郑州美健健康管 理有限公司47.37%少数股权、广州花都区美年大健康管理有限公司49.00%少数 股权、安徽美欣健康管理咨询有限公司42.4 ...

2025 年 07 月 10 日 本资产评估报告依据中国资产评估准则编制 美年大健康产业控股股份有限公司拟发行股份购买资产所涉及的 宁德美年大健康管理有限公司股东全部权益价值 资产评估报告 金证评报字【2025】第 0377 号 （共一册，第一册） 金证（上海）资产评估有限公司 | 报告编码: | 3132020024202500412 | | | --- | --- | --- | | 合同编号: | 金证评合约字【2025】第04070号 | | | 报告类型: | 法定评估业务资产评估报告 | | | 报告文号: | 金证评报字【2025】第0377号 | | | 报告名称: | 美年大健康产业控股股份有限公司拟发行股份购买资产所涉及的 宁德美年大健康管理有限公司股东全部权益价值资产评估报告 | | | 评估结论: | 47.500.000.00元 | | | 评估报告日 : | 2025年07月10日 | | | 评估机构名称: | 金证(上海)资产评估有限公司 | | | 签名人员: | 马翊君 (资产评估师) 正式会员 编号:31190140 | | | | 刘怡青 正式会员 编号:3119014 ...